http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
A microcell $UO_2$ pellet, as an accident-tolerant fuel pellet, is being developed to enhance the accident tolerance of nuclear fuels under accident conditions as well as the fuel performance under normal operation conditions. Improved capture-ability for highly radioactive and corrosive fission product (Cs and I) is the distinct feature of a ceramic microcell $UO_2$ pellet, and the enhanced pellet thermal conductivity is that of a metallic microcell $UO_2$ pellet. The fuel temperature can be effectively decreased by enhanced thermal conductivity. In this study, the material concepts of metallic and ceramic microcell $UO_2$ pellets were designed, and the fabrication process of microcell $UO_2$ pellets embodying the designed concept was developed. We successfully implemented the microcell $UO_2$ pellets and produced microcell $UO_2$ pellets. In addition, an assessment of the out-of-pile properties of a microcell $UO_2$ pellet was performed, and the in-reactor performance and behavior of the developed microcell pellets were evaluated through a Halden irradiation test. According to the expectations, the excellent performance of the microcell $UO_2$ pellets was confirmed by the online measurement data of the Halden irradiation test.
Koo, Hye Ryoung,Park, Jeong Seon,Kang, Keon Wook,Cho, Nariya,Chang, Jung Min,Bae, Min Sun,Kim, Won Hwa,Lee, Su Hyun,Kim, Mi Young,Kim, Jin You,Seo, Mirinae,Moon, Woo Kyung Springer-Verlag 2014 EUROPEAN RADIOLOGY Vol.24 No.3
Kim, Hyun-Young,Lee, Soo Hyun,Lee, Mi-Na,Kim, Jong-Won,Kim, Young-Ho,Kim, Mi Jin,Lee, Yoo Min,Kang, Ben,Choe, Yon Ho,Lee, Na Hee,Kim, Dong Hwan,Yoo, Keon Hee,Sung, Ki Woong,Lee, Soo-Youn,Koo, Hong Hoe Wolters Kluwer Health, Inc. All rights reserved. 2015 PHARMACOGENETICS AND GENOMICS Vol.25 No.3
Thiopurine S-methyltransferase (TPMT) is a cytoplasmic enzyme involved in the metabolism of thiopurine drugs and its activity is largely influenced by polymorphisms of the TPMT gene. To date, more than 35 TPMT variants are known to be associated with reduced enzyme activity, but most studies on the TPMT genotype have included only common nonfunctional variants, such as TPMT*2 and TPMT*3. In this study, we carried out a complete sequencing analysis to screen all TPMT variants in Korean patients. A total of 900 Korean patients were genotyped for TPMT and 30 patients (3.3%) had the known TPMT variant alleles. TPMT*3C was found in 25 patients (2.8%): 24 patients with TPMT*1/*3 and one with TPMT*3/*3. Rare TPMT variants including TPMT*6, TPMT*16, and TPMT*32 were detected in five patients (0.6%) and a novel variant, TPMT*38 (c.514T>C, p.S172P), was identified in two patients. This is the first complete sequence-based screening study evaluating all TPMT variants in Asian populations.
Scabies is a highly contagious skin infestation caused by the mite, Sarcoptes scabiei var. hominis. Complex responses to scabies mites in the innate, humoral, and cellular immune systems can cause skin inflammation and pruritus. Diagnosis can be challenging because scabies resembles other common skin conditions. We report the first Korean case of scabies in a hematopoietic cell transplant (HCT) recipient, initially suspected of skin graft versus host disease (GVHD). A T-cell acute lymphocytic leukemia patient underwent a sibling-matched allogeneic HCT and developed pruritus after cell engraftment. Treatment for GVHD did not improve the symptoms. He was diagnosed with scabies 30 days after the onset of symptoms.
<P><B>Abstract</B></P> <P>As one of accident tolerant fuel pellets which should have features of good thermal conductivity and high fission product retention, a micro-cell UO<SUB>2</SUB>–Mo pellet has been studied in the aspect of fabrication and thermal property. It was intended to develop the compatible process with conventional UO<SUB>2</SUB> pellet fabrication process. The effects of processing parameters such as the size and density of UO<SUB>2</SUB> granule and the size of Mo powder have been studied to produce sound and dense pellet with completely connected uniform Mo cell-walls. The micro-cell UO<SUB>2</SUB>–Mo pellet consists of many Mo micro-cells and UO<SUB>2</SUB> in them. The thermal conductivity of the micro-cell UO<SUB>2</SUB>–Mo pellet was measured and compared to those of the UO<SUB>2</SUB> pellet and the UO<SUB>2</SUB>–Mo pellet with dispersed form of Mo particles. The thermal conductivity of the micro-cell UO<SUB>2</SUB>–Mo pellet was much enhanced and was found to be influenced by the Mo volumetric fraction and pellet integrity. A continuous Mo micro-cell works as a heat conducting channel in the pellet, greatly enhancing the thermal conductivity of the micro cell UO<SUB>2</SUB>–Mo pellet.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Accident tolerant fuel pellets with features of good thermal conductivity and high fission product retention, a micro-cell pellet has been studied. </LI> <LI> Effects of processing parameters have been studied to produce sound and dense pellet with completely connected uniform Mo cell-walls. </LI> <LI> The thermal conductivity of the micro-cell UO<SUB>2</SUB>–Mo pellet was remarkably enhanced. </LI> </UL> </P>
배경: 유전성 대사질환의 치료로서 효소 요법 및 유전자 치료가 제한적인 현실에서 동종 조혈모세포이식이 현재로선 가장 중요한 치료가 될 수 있다. 본 연구에서는 단일 기관에서 유전성 대사질환에 대해 동종 조혈모세포이식을 시행한 경험을 보고하고자 하였다. 방법: 삼성서울병원 유전성 대사질환 조혈모세포이식팀에서는 1999년 12월부터 2001년 3월까지 총 6례의 유전성 대사질환을 대상으로 동종 조혈모세포이식을 시행하였다. 대상 질환은 Hunter 증후군 3례, galactosialidosis 1례, 이염성 백질이영양증 1례, 부신백질이영양증 1례였으며 성별 분포는 남아가 5명, 여아가 1명이었으며 연령 분포는 2년 9개월에서 15년 9개월이었다. 5례는 HLA 일치 혈연간 골수이식이었으며 1례는 HLA 불일치 T 림프구 제거 말초혈액 조혈모세포이식이었다. 전처치는 모두 BuCy를 사용하였으며 이식편대숙주반응의 예방에는 cyclosporine을 사용하였다. 이식된 세포는 유핵세포가 4.81×10^(8)(2.40~7.01×10^(8))/kg이었으며 CD34+ 세포는 3.65×10^(6)(0.88~10.72×10^(6))/kg이었다. 결과: 이식 후 조혈기능의 회복은 모두 조기에 달성되었으며(ANC>500: 정중 9.5일, 범위 9~14일; PLT>50K: 정중 32일, 범위 23~34일) 이식과 관련된 합병증은 Gr I의 aGVHD 3례, 국한성의 cGVHD 1례, 경증의 간정맥 폐쇄성 질환이 1례이었다. 모든 환자에서 직간접적으로 이식 후 효소의 생산이 증가함이 확인되었으며 임상적인 호전을 보인 경우가 4례, 질병 진행이 중단된 경우가 1례, 질병이 진행된 경우가 1례이었다. 질병 진행이 중단되었던 1례는 면역억제제 투여 중 수두 감염에 의한 폐출혈로 사망하였다. 결론: 유전성 대사질환에서 동종 조혈모세포이식이 가장 중요한 치료법으로 사용될 수 있고 중추신경계 증상이 나타나기 전, 가능한 조기에 조혈모세포이식을 시행하는 것이 바람직할 것이며 적극적인 지지 요법이 필요하다. 향후 더 많은 임상 경험이 필요하리라 사료된다. Background: Allogeneic hematopoietic stem cell transplantation (HSCT) may be the most important treatment modality to cure a number of genetic metabolic disorders because of the limitation of enzyme replacement or gene therapy. In this study, we report our single center experience about HSCT in several genetic metabolic disorders. Methods: We performed 6 cases of HSCT for genetic metabolic disorders from December 1999 to March 2001. Patients' diagnoses were Hunter syndrome (3), galactosialidosis (1), metachromatic leukodystrophy (1), and adrenoleukodystrophy (1). Stem cell sources were bone marrow from HLA matched sibling donors in 5 patients and mother's peripheral blood stem cells in one patient who did not have HLA matched donors. Busulfan and cyclophosphamide for conditioning, and cyclosporine for the prevention of graft versus host disease were used in all patients. Transplanted total nucleated cell counts were median 4.81×10^(8)(2.40~7.01×10^(8))/kg , and CD34+ cells 3.65×10^(6)(0.88~10.72×10^(6))/kg. Results: All patients achieved early hematologic recovery (median 9.5 days, range 9~14 days for ANC>500/μL; median 32 days, range 23~34 days for PLT>50,000/μL). Transplant-related complications were 3 cases of grade 1 acute GVHD, a case of limited chronic GVHD, and a case of mild hepatic veno-occlusive disease. Enzyme levels were normalized in 4 patients evaluated and there were indirect evidences of enzyme production in the other 2 patients after HSCT. Four of the 6 patients showed symptomatic improvement, 1 patient (galactosialidosis) experienced disease stabilization without progression before he eventually died due to pulmonary hemorrhage, and the other 1 patient deteriorated progressively even after HSCT. Conclusions: Allogeneic HSCT can be done as the only curative treatment in a number of genetic metabolic disorders. It seems desirable to perform HSCT as early as possible before the onset of central nervous system symptoms. More experience and long term follow up is needed to evaluate the efficacy and to monitor the long term transplant-related complications.
김건열 ( Keon Youl Kim ),이계영 ( Kye Young Lee ),현인규 ( In Kyu Hyun ),김영환 ( Young Whan Kim ),한성구 ( Sung Koo Han ),심영수 ( Young Soo Shim ),한용철 ( Yong Chol Han ) 대한결핵 및 호흡기학회 1992 Tuberculosis and Respiratory Diseases Vol.39 No.6
Song, Keon-Hyoung,Kim, Sang-Bum,Shim, Chang-Koo,Chung, Suk-Jae,Kim, Dae-Duk,Rhee, Sang-Ki,Choi, Guang J,Kim, Chul-Hyun,Kim, Kiyoung Dove Medical Press 2015 Drug design, development and therapy Vol.9 No.-
<P><B>Background</B></P><P>The identification of permeation enhancers has gained interest in the development of drug delivery systems. A six-mer peptide, H-FCIGRL-OH (AT1002), is a tight junction modulator with promising permeation-enhancing activity. AT1002 enhances the transport of molecular weight markers or agents with low bioavailability with no cytotoxicity. However, AT1002 is not stable in neutral pH or after incubation under physiological conditions, which is necessary to fully uncover its permeation-enhancing effect. Thus, we increased the stability or mitigated the instability of AT1002 by modifying its terminal amino acids and evaluated its subsequent biological activity.</P><P><B>Methods</B></P><P>C-terminal-amidated (FCIGRL-NH<SUB>2</SUB>, Pep1) and N-terminal-acetylated (Ac-FCIGRL, Pep2) peptides were analyzed by liquid chromatography–mass spectrometry. We further assessed cytotoxicity on cell monolayers, as well as the permeation-enhancing activity following nasal administration of the paracellular marker mannitol.</P><P><B>Results</B></P><P>Pep1 was nontoxic to cell monolayers and showed a relatively low decrease in peak area compared to AT1002. In addition, administration of mannitol with Pep1 resulted in significant increases in the area under the plasma concentration–time curve and peak plasma concentration at 3.63-fold and 2.68-fold, respectively, compared to mannitol alone. In contrast, no increase in mannitol concentration was shown with mannitol/AT1002 or mannitol/Pep2 compared to the control. Thus, Pep1 increased the stability or possibly reduced the instability of AT1002, which resulted in an increased permeation-enhancing effect of AT1002.</P><P><B>Conclusion</B></P><P>These results suggest the potential usefulness of C-terminal-amidated AT1002 in enhancing nasal drug delivery, which may lead to the development of a practical drug delivery technology for drugs with low bioavailability.</P>